scholarly article | Q13442814 |
P356 | DOI | 10.2217/FON.14.20 |
P698 | PubMed publication ID | 24941977 |
P2093 | author name string | Sanjay Dixit | |
P2860 | cites work | Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma? | Q34480557 |
Basic concepts of immunology and neuroimmunology | Q36525975 | ||
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | immunotherapy | Q1427096 |
P304 | page(s) | 911-915 | |
P577 | publication date | 2014-05-01 | |
P1433 | published in | Future Oncology | Q2781597 |
P1476 | title | Immunotherapy for high-grade glioma | |
P478 | volume | 10 |
Q52776751 | Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype. |
Q36705896 | Glioma-derived extracellular vesicles selectively suppress immune responses |
Q47967336 | Preliminary results of immune modulating antibody MDV9300 (pidilizumab) treatment in children with diffuse intrinsic pontine glioma |
Q35741739 | Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma |
Q26797282 | The progress of immunotherapy for glioblastoma |
Q54942652 | Trends in Malignant Glioma Monoclonal Antibody Therapy. |
Search more.